Tumor-Infiltrating Lymphocytes (TIL), Tertiary Lymphoid Structures (TLS), and Expression of PD-1, TIM-3, LAG-3 on TIL in Invasive and In Situ Ductal Breast Carcinomas and Their Relationship with Prognostic Factors

Clin Breast Cancer. 2022 Dec;22(8):e901-e915. doi: 10.1016/j.clbc.2022.08.005. Epub 2022 Aug 20.

Abstract

Introduction: Immunotherapy has been determined as an important choice in breast carcinomas, especially in tumors with markedly inflammatory response. About this promising subject, tumor-infiltrating lymphocytes (TIL) and the expression of immune control point receptors on TIL have gained importance.

Materials and methods: In this study, stromal TIL and tertiary lymphoid structures (TLS) were determined in tumor tissues of 312 invasive and 68 in situ breast cancer patients. Expression rates of PD-1, LAG-3, and TIM-3 on intratumoral and stromal TIL were immunohistochemically evaluated.

Results: In invasive breast carcinomas, stromal TIL was found to be significantly associated with lymph node metastasis, HR and HER2 expression, and basal-like phenotype, as the presence of TLS with neoadjuvant therapy, recurrence, death, and expression of HR and HER2. PD-1, LAG-3, and TIM-3 expressions were found to be associated with HR and HER2 status, stromal TIL rates, and TLS. In multivariate analysis, high stromal TIL and PD-1 expression in intratumoral TIL were found to be independent prognostic factors in terms of overall survival and disease-free survival.

Conclusion: Evaluation of TIL and immune control point receptor expressions in breast cancer is particularly important in terms of planning the therapeutic approaches based on immunotherapy protocols.

Keywords: Breast cancer prognosis; Breast cancer treatment; Immune checkpoint molecules; Immunotherapy; Tumor immunology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Carcinoma, Intraductal, Noninfiltrating* / pathology
  • Female
  • Hepatitis A Virus Cellular Receptor 2 / therapeutic use
  • Humans
  • Lymphocytes, Tumor-Infiltrating
  • Prognosis
  • Programmed Cell Death 1 Receptor
  • Tertiary Lymphoid Structures* / pathology

Substances

  • Programmed Cell Death 1 Receptor
  • Hepatitis A Virus Cellular Receptor 2